Dr Reddy's gets DCGI nod for Zytorvi in advanced esophageal cancer

Dr. Reddy's Laboratories announced that the Central Drugs Standard Control Organisation (CDSCO) has approved Zytorvi® (toripalimab) in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). This marks the second approved indication for Zytorvi® in India, expanding its use beyond nasopharyngeal carcinoma. The approval, based on the Phase 3 JUPITER-06 trial, showed a 42% reduction in the risk of disease or death. Dr. Reddy's entered into a licensing and commercialization agreement with Junshi Biosciences in 2023 for toripalimab across 21 countries. Toripalimab is also approved by USFDA, EMA, and MHRA.